A Long-Term Study of MP-214 in Patients With Receiving Multiple Drugs Schizophrenia
Phase of Trial: Phase II/III
Latest Information Update: 25 Aug 2015
At a glance
- Drugs Cariprazine (Primary)
- Indications Schizophrenia
- Focus Adverse reactions
- Sponsors Mitsubishi Tanabe Pharma Corporation
- 25 Aug 2015 According to an Allergan media release, pooled data from phase II/III studies will be presented at the 28th European College of Neuropsychopharmacology (ECNP) annual congress.
- 28 Jan 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 22 Jan 2014 Status changed from recruiting to active, no longer recruiting ar reported by ClinicalTrials.gov record.